Posted On: 12/16/2015 11:39:26 AM
Post# of 72446
All excellent points/info, doubleJ23. The Dana-Farber thing is really interesting, especially since that guy affiliated with Dana-Farber is now going to Novartis to head up their research department.
To all who claim that the Kevetrin trial is somehow not working (despite so much evidence that it IS working, even with just the weekly doses), as you say the fact that D-F wants to continue the trial shows how important they think the results are.
To all who claim that the Kevetrin trial is somehow not working (despite so much evidence that it IS working, even with just the weekly doses), as you say the fact that D-F wants to continue the trial shows how important they think the results are.
Quote:
Also, even though Leo mentions the ABSSSI market which B will do well in, but the real $$ for antibiotics will come from other indications. ABSSSI is just the gateway, not the end game.
Regarding K, I just want to reiterate he made a point to note that it is very unusual for DF to offer to extend the trial. Also, Leo said he needs to wait until his next meeting with the FDA before giving us more K info. I forget if that was for January or just early 2016, but that means we could get a K update soon.
Read More: http://investorshangout.com/post/view?id=3421...z3uVDSfg5Z
(0)
(0)
